- PR Newswire•last monthThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company, focused on developing novel medicines for diabetic eye disease, announces the enrollment of the first patients in a Phase II, single-masked, multicenter exploratory study evaluating the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular edema (DME). THR-317 (anti-PIGF) is a recombinant human monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF). The trial will also assess THR-317's ability to improve best-corrected visual acuity (BCVA) and to reduce central retinal thickness in subjects with DME.
- PR Newswire•6 months agoThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)
LEUVEN, Belgium, August 8, 2016 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the results ...
- PR Newswire•8 months ago
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for back of the eye disease, today announces that the Office of Biotechnology Products of the U.S. Food and Drug Administration (FDA) has approved a new already-diluted formulation of its JETREA® (ocriplasmin). The new formulation of JETREA® offers the additional benefit of eliminating the current preparatory dilution steps prior to injection.
THR.BR : Summary for THROMBOGENICS - Yahoo Finance
ThromboGenics NV (THR.BR)
Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
|Bid||2.96 x 10000|
|Ask||3.01 x 500000|
|Day's Range||3.33 - 3.48|
|52 Week Range||2.50 - 3.88|
|PE Ratio (TTM)||-3.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|